This study demonstrates the validity of developing Hsp70 co-chaperone inhibitors to sensitize cells to current anticancer therapies and suggests that determining DNAJA1 status of a tumor may be beneficial in selecting the most appropriate course of treatment. The gene discussed is DNAJA1; the disease is neoplasm.